EPO Patents = 1

Forward Citations = 3

Loading Chart...

11 inventors (with patents filed for the assignee):

Ke Yu (3 out of 13 patents)

Xuesai Zhang (3 out of 4 patents)

Qing Lin (3 out of 3 patents)

4. Qingrou Li (3 out of 4 patents)

5. Tao Meng (2 out of 9 patents)

6. Jingkang Shen (2 out of 18 patents)

7. Lanping Ma (2 out of 7 patents)

8. Chaohong Hu (2 out of 2 patents)

9. Hu Li (1 out of 7 patents)

10. Wenchao Liu (1 out of 1 patent)

11. Zhenyu Dai (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 12290505 - Tissue factor-targeted antibody-drug conjugate (2025-05-06),

2. 12103978 - Methods and materials for treating cancer (2024-10-01),

3. 11534495 - Tissue factor-targeted antibody-drug conjugate (2022-12-27),

4. 10792370 - Antibody-drug conjugate (2020-10-06),

5. 10676537 - Antibody targeted to tissue factor, preparation method therefor, and use thereof (2020-06-09),

Shanghai Miracogen Inc. is a biotechnology company focused on the development and commercialization of innovative immuno-oncology therapies. Established in Shanghai, the company leverages cutting-edge technology to create novel treatments aimed at enhancing the immune response against various forms of cancer. With a strong commitment to research and development, Miracogen aims to improve patient outcomes through targeted therapies that harness the body's immune system. Their pipeline includes several promising candidates currently in clinical trials, addressing unmet medical needs in oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

5 Patents

#389 in Shanghai

#4,534 in China

Shanghai, China

Shanghai Miracogen Inc